Phil Gutry is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
The reporting person resigned as a director of Avalo Therapeutics, Inc. effective December 1, 2021. As a result, the reporting person is no longer subject to Section 16 in connection with their transactions in the equity securities of Avalo Therapeutics, Inc. and therefore will no longer report any such transactions on Form 4 or Form 5.